New York, June 12, 2024 - PRISM MarketView - Leading developer of innovative surgical robotic technologies, SS Innovations International (OTC: SSII) has secured regulatory approval from the Indonesian Ministry of Health for clinical use for the use of its flagship surgical robotic system, the SSi Mantra, in the Republic of Indonesia. Indonesia has a population of approximately 280 million and is the world’s fourth most populous country.
“With the entry of the SSi Mantra to the Indonesian market, we believe that we can be instrumental in increasing access to and decreasing costs of robotic surgery options. We look forward to broadening surgical horizons for Indonesians and continuing to expand our innovative surgical services and options across the globe.”
Dr. Sudhir Srivastava, SS Innovation’s Chairman and CEO
Robotic surgery has been slow to be adopted in Indonesia, where the nation’s Bunda Hospital in Jakarta acquired its first robotic surgical system in 2012 and has only completed about 700 surgeries to date.
The SSi Mantra is one of the only systems in the world designed to be cost-effective with broad-spectrum surgical applications. SS Innovations is working to secure regulatory approval in the United States and the European Union.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities